Edwards Lifesciences Stock Rises After Q2 Beat and Upgraded Guidance
Edwards Lifesciences shares climbed after the company posted second-quarter 2026 results that outperformed analyst estimates and raised the lower bound of its full-year sales-growth forecast. Revenue and adjusted earnings topped consensus, TAVR and TMTT segments reported robust growth, and multiple brokerages lifted price targets and ratings, suppo…